Fortis

Algeta ASA (OSL:ALGETA) Major milestone reached as phase III trial with Alpharadin in advanced prostate cancer begins

Algeta ASA (OSL:ALGETA) Oslo, Norway, 12 August 2008 - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, has started the first US clinical trial for its lead product Alpharadin in men with hormone-refractory prostate cancer (HRPC) that has metastasized to the skeleton.

Algeta ASA (OSL:ALGETA) Oslo, Norway, 11 August 2008 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, will announce its second quarter 2008 results on Wednesday, 13 August 2008. A presentation to investors, analysts and the press will take place in Oslo at 08:15 CET and an international conference call will take place at 14:30 CET (details below). Algeta's President and Chief Executive Officer, Dr. Thomas Ramdahl and Chief Financial Officer, Øystein Soug will host the presentation and the call will be hosted by Thomas Ramdahl.

Algeta ASA Oslo, Norway, 19 June 2008 - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that positive biodistribution and dosimetry data for its lead cancer therapy Alpharadin was presented yesterday at the 55th Annual Meeting of the Society for Nuclear Medicine in New Orleans, USA. The data were presented in an oral presentation by Dr. Cecilia Hindorf on behalf of the Royal Marsden Hospital (Sutton, UK), entitled "A biodistribution and dosimetry study of therapeutic 223Ra-chloride (Alpharadin) in patients with osteoblastic skeletal metastases secondary to hormone refractory prostate cancer."

Algeta ASA Oslo, Norway, 18 June 2008 - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, has started patient recruitment in a pivotal phase III clinical study of its targeted therapeutic Alpharadin in advanced, hormone-refractory prostate cancer (HRPC) that has metastasized to the skeleton. This development follows the publication of phase II results showing that Alpharadin treatment provides a significant survival benefit in metastatic HRPC patients compared to placebo.